North America Autoinjectors Market

Market Overview

The North American autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 15.3% during the forecast period (2023-2030).

Highlights

• Anaphylaxis dominates the market by therapy.
• Disposable dominates the market by type.
• Homecare dominates the market by end-user.

Autoinjectors are pre-filled syringes with a tip held in place by a spring. When a sliding motion is used to inject the device into the body, it turns on and gives a measured dose of a medicine. Autoinjectors are used to give yourself epinephrine to avoid anaphylaxis or to quickly relieve pain from a migraine, as well as for other medical and emergency treatments. Autoinjectors have several benefits, such as making people less afraid of needles, lowering the chance of getting a needle stuck, keeping the dose quality consistent, and helping people be more successful.

Market Dynamics

North America Autoinjectors Market Drivers

Increasing Incidences of Anaphylactic Shock

Anaphylactic shock demands immediate medical attention. EpiPens, which give epinephrine in an anaphylactic emergency, are autoinjectors. According to CDC data, food allergies, a primary cause of anaphylactic shock, are rising in the U.S. Food allergies in children under 18 increased by 50% between 1997 and 2011. Common allergens include peanuts, tree nuts, shellfish, milk, eggs, and soy. Thus, this factor can act as a major driver in the market.

North America Autoinjectors Market Restraints

Increasing Preference for Alternative Drug Delivery Modes

Oral medication, inhalation devices, and transdermal patches have advanced in the North American pharmaceutical sector. These alternatives increase patient compliance, convenience, and autoinjector demand. Patients may choose oral or non-invasive delivery techniques over injections. Due to their widespread use, oral drugs are convenient and familiar. This slows market growth.

North America Autoinjectors Market Opportunities

Streamline Regulatory Guidelines

In North America, simplifying rules has opened up possibilities for growth in the autoinjectors market. Regulatory bodies like the FDA have made the approval process easier, reducing the time and money needed for product creation and entry. This has led to faster entry to the market, lower costs, more innovation, and easier access for patients to more advanced autoinjector devices.  Streamlining rules has helped the industry grow by increasing players, encouraging innovation, and ensuring people get better treatments quickly.

Regional Analysis

The North American autoinjectors market is analyzed by country in the U.S., Canada, and Mexico. The U.S. dominated the market and is expected to grow at a CAGR of 15.2% during the forecast period.

In 2022, North America made the most revenue in the autoinjectors market. This is because many people have diseases and have better access to improved treatments for anaphylaxis. Since rheumatoid arthritis, anaphylaxis, diabetes, migraines, heart disease, and food allergies are becoming more common, there is a high demand for autoinjectors.

U.S

During the time frame of the forecast, the United States autoinjectors market is projected to have a large share of the North American market. The market is growing because of the rise in chronic and specific diseases, the number of regulatory approvals, and technological advances in the healthcare industry. According to Food Allergy Research and Education, about 33.1 million Americans have food allergies. This includes 5.99 million children under 18 years old, one in thirteen. Since more people have anaphylaxis and other allergies in the United States, the FDA has to approve new products more quickly. Self-administered drugs are in higher demand because more people have chronic and inflammatory diseases.

On the other hand, according to the Centers for Disease Control and Prevention, 24% of adults in the U.S., or 58.5 million people, have arthritis. It is the top cause of work disability, costing $303.5 billion annually in medical care and lost wages. Also, the most common type of arthritis is osteoarthritis. When doctors say someone has arthritis, it is hard for them to do their daily tasks.

Canada

The Canadian autoinjectors market is also expected to have a high growth rate in terms of revenue. This is because Canada has a more advanced healthcare system, more people want quality goods, and the government is investing more money. Canada's market is growing because more people are getting chronic diseases, paying attention to their health, and using autoinjectors to give themselves drugs. Bausch Health, Canada, said in an October 2020 release that EmeradeTM epinephrine autoinjectors are now available in pharmacies all over Canada. Emerade is a new autoinjector for epinephrine that gives Canadians a second choice. More people will be able to get autoinjector goods, which will help the market grow in the country as a whole.

Segmental Analysis

The North American autoinjectors market is segmented based on therapy, type, end-user, and country.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, cardiovascular diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 14.2% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 14.5% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 16.1% during the forecast period.

Recent Developments

• May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.
• April 2023- Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") selected the target AVERSATM formulation for commercial scale manufacturing process development for the Company's patented lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system.